Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 1152 record(s)

Req # A-2022-001004

Adverse Drug Reactions (ADRs) for C1 Esterase Inhibitor (Human). Report numbers: E2B_05697513, E2B_05662863, E2B_05676847. ADRs for Immunoglobulin (human). Report numbers: E2B_05654955, E2B_05650332, E2B_05626265, E2B_05638123, E2B_05675217. ADR for REPLAGAL. Report number: E2B_05645576. ADR for Lanadelumab. Report number: E2B_05662049.

Organization: Health Canada

139 page(s)
January 2023

Req # A-2022-001005

Adverse Drug Reaction (ADR) for Dexilant. Report number: E2B_05679330. ADR for Entyvio. Report number: E2B_05636147. ADRs for Vedolizumab. Report numbers: E2B_05710173, E2B_05621550, 001006464, E2B_05612446. ADR for Ixazomib. Report number: E2B_05641996. ADR for ADDERALL XR. Report number: 001008189. ADRs for Amphetamine. Report numbers: 001007205, E2B_05661529.

Organization: Health Canada

366 page(s)
January 2023

Req # A-2022-001009

Adverse Drug Reactions (ADRs) for BISACODYL AND DOCUSATE SODIUM. Report numbers: 001006655, 001006867, E2B_05628348, E2B_05657880, E2B_05628332.

Organization: Health Canada

165 page(s)
January 2023

Req # A-2022-001023

Adverse Drug Reactions (ADRs) for Januvia. Report numbers: E2B_02958375, E2B_03435748, E2B_03207281, E2B_03014229, E2B_03480899, E2B_04284040, 000918607, 000650406.

Organization: Health Canada

188 page(s)
January 2023

Req # A-2022-001026

Adverse Drug Reaction (ADR). Report number: E2B_03070528.

Organization: Health Canada

280 page(s)
January 2023

Req # A-2022-001029

Adverse Drug Reactions (ADRs) for Morphine. Report numbers: 001008181, 001004520. ADRs for Hydromorphone. Report numbers: 0001006182, E2B_04321175, E2B_04699858, E2B_04841607.

Organization: Health Canada

95 page(s)
January 2023

Req # A-2022-001040

Adverse Drug Reactions (ADRs). Report numbers: E2B_05631885, E2B_05636120, E2B_05556948.

Organization: Health Canada

24 page(s)
January 2023

Req # A-2022-001041

Adverse Drug Reactions (ADRs). Report numbers: E2B_05653106, E2B_05632251, E2B_05635022, E2B_05653113, E2B_05643492.

Organization: Health Canada

68 page(s)
January 2023

Req # A-2022-001069

Adverse Drug Reactions (ADRs). Report numbers: 000994718, 001008281.

Organization: Health Canada

16 page(s)
January 2023

Req # A-2022-001082

Adverse Drug Reactions (ADRs) for CELEXA. Report numbers: E2B_04793638, E2B_04694880, E2B_03387893, E2B_04885161, 00975612, 00977234, 00978744, 00981330, E2B_05032996, 00978796.

Organization: Health Canada

121 page(s)
January 2023
Date modified: